Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine.

TitleEvolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine.
Publication TypeJournal Article
Year of Publication2022
AuthorsPatel SM, Shaik-Dasthagirisaheb YB, Congdon M, Young RR, Patel MZ, Mazhani T, Boiditswe S, Leburu T, Lechiile K, Arscott-Mills T, Steenhoff AP, Feemster KA, Shah SS, Cunningham CK, Pelton SI, Kelly MS
JournalPLoS One
Volume17
Issue1
Paginatione0262225
Date Published2022
ISSN1932-6203
Abstract

Pneumococcal conjugate vaccines reduce the burden of invasive pneumococcal disease, but the sustained effect of these vaccines can be diminished by an increase in disease caused by non-vaccine serotypes. To describe pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine (PCV-13) in July 2012, we performed molecular serotyping of 268 pneumococcal strains isolated from 221 children between 2012 and 2017. The median (interquartile range) age of the children included in this analysis was 6 (3,12) months. Fifty-nine percent of the children had received at least one dose of PCV-13 and 35% were fully vaccinated with PCV-13. While colonization by vaccine serotypes steadily declined following PCV-13 introduction, 25% of strains isolated more than 3 years after vaccine introduction were PCV-13 serotypes. We also observed an increase in colonization by non-vaccine serotypes 21 and 23B, which have been associated with invasive pneumococcal disease and antibiotic resistance in other settings.

DOI10.1371/journal.pone.0262225
Alternate JournalPLoS One
PubMed ID34986196
PubMed Central IDPMC8730465